Associated Papers
Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms.
Kim HY et al.
Diagnostics (basel, Switzerland), 2022
Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.
Loscocco GG et al.
Cells, 2021
Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data.
Loscocco GG et al.
Oncotargets and Therapy, 2020
Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
Zuo Z et al.
Current Hematologic Malignancy Reports, 2019
Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2019
Mayo CALR mutation type classification guide using alpha helix propensity.
Lasho TL et al.
American Journal of Hematology, 2018
Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
Patel U et al.
Clinical Lymphoma, Myeloma & Leukemia, 2017
Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients.
Yoo EH et al.
Journal of Clinical Laboratory Analysis, 2016
Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG et al.
Oncotarget, 2016
JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.
Shirane S et al.
Haematologica, 2015
Calreticulin mutations and long-term survival in essential thrombocythemia.
Tefferi A et al.
Leukemia, 2014
Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Broséus J et al.
Leukemia, 2014
CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
Smaili W et al.
Current Research in Translational Medicine, 0
Select a paper to view details